Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatment

by

Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.

Leave A Comment

Your email address will not be published. Required fields are marked *